Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
03 Luglio 2023 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2023
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
EXPLANATORY
NOTE
As of June 30, 2023, BiondVax Pharmaceuticals
Ltd. (the “Company”) satisfied the conditions to qualify as a “foreign private issuer” under Rule 3b-4 of the
Securities Exchange Act of 1934, as amended. Accordingly, commencing as of July 1, 2023, the Company will file with the Securities and
Exchange Commission such periodic reports required of¸ and shall otherwise be subject to the requirements imposed under U.S. federal
securities laws on, foreign private issuers.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
BiondVax Pharmaceuticals Ltd. |
|
|
|
By: |
/s/ Amir Reichman |
|
|
Amir Reichman |
|
|
Chief Executive Officer |
|
|
July 3, 2023 |
|
2
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2023 a Mag 2024